title: [Trans-arterial embolization or transarterial infusion of anti-cancer drugs suspended in a lipid contrast medium against unresectable metastatic liver cancer].
abstract: We had 84 patients with unresectable metastatic liver cancer from May, 1980 to December 1987 in the National Matsudo Hospital. Eighteen of them had no treatment; 26 of them had serial transarterial embolization (TAE) with or without infusion of anti-cancer drug dispersed in lipiodol; 7 of them had only serial trans-arterial infusion (L-TAI) of an anticancer drug suspended in lipiodol. A significant survival advantage of patients with TAE or L-TAI was noted when compared with no treatment, but there was no difference between the survival rate of patients with TAE and L-TAI. There were some 82 patients with unresectable metastatic liver cancer from October 1984 to March 1988 in Kyto Prefectural University of Medicine Hospital. Thirteen of them had L-TAI using one anti-cancer drug (one-drug group); 8 of them had L-TAI using two drugs (two-drug group); 22 of them had L-TAI with three drugs (three-drug group). The survival rate of the three-drug group was superior to the one- and two-drug groups. It was concluded that TAE was not necessary for metastatic liver cancer, but L-TAI must be undertaken, because combined cancer chemotherapy enhanced the effect of L-TAI.
authors.affiliation: 1st Dept. of Surgery, Kyoto Prefectural University of Medicine.
authors.forename: H
authors.initials: H
authors.lastname: Taniguchi
authors.forename: Y
authors.initials: Y
authors.lastname: Shioaki
authors.forename: A
authors.initials: A
authors.lastname: Itoh
authors.forename: K
authors.initials: K
authors.lastname: Seiki
authors.forename: M
authors.initials: M
authors.lastname: Shimotsuma
authors.forename: T
authors.initials: T
authors.lastname: Yamaguchi
authors.forename: K
authors.initials: K
authors.lastname: Sawai
authors.forename: T
authors.initials: T
authors.lastname: Takahashi
authors.forename: S
authors.initials: S
authors.lastname: Kitai
authors.forename: Y
authors.initials: Y
authors.lastname: Shimamura
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000627:therapeutic use; D004317:Doxorubicin / Q000008:administration & dosage; D004621:Embolization, Therapeutic; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial; D007459:Iodized Oil / Q000008:administration & dosage*; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary / Q000628:therapy*; D008299:Maleic Anhydrides / Q000008:administration & dosage; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D011137:Polystyrenes / Q000008:administration & dosage; D011379:Prognosis; D013535:Suspensions; D009353:Zinostatin / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D008299:Maleic Anhydrides; D008937:Mitomycins; D011137:Polystyrenes; D013535:Suspensions; C035755:poly(maleic acid-styrene)neocarzinostatin; D016685:Mitomycin; D007459:Iodized Oil; D004317:Doxorubicin; D009353:Zinostatin; C017367:carmofur; D005472:Fluorouracil